Cargando…
Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates
Malaria transmission blocking vaccines (TBV) aim to induce antibodies that can interrupt Plasmodium falciparum development in the mosquito midgut and thereby prevent onward malaria transmission. A limited number of TBV candidates have been identified and only three (Pfs25, Pfs230 and Pfs48/45) have...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259988/ https://www.ncbi.nlm.nih.gov/pubmed/35812379 http://dx.doi.org/10.3389/fimmu.2022.909060 |
_version_ | 1784741913171066880 |
---|---|
author | de Jong, Roos M. Singh, Susheel K. Teelen, Karina van de Vegte-Bolmer, Marga van Gemert, Geert-Jan Stone, Will J. R. Locke, Emily Plieskatt, Jordan Theisen, Michael Bousema, Teun Jore, Matthijs M. |
author_facet | de Jong, Roos M. Singh, Susheel K. Teelen, Karina van de Vegte-Bolmer, Marga van Gemert, Geert-Jan Stone, Will J. R. Locke, Emily Plieskatt, Jordan Theisen, Michael Bousema, Teun Jore, Matthijs M. |
author_sort | de Jong, Roos M. |
collection | PubMed |
description | Malaria transmission blocking vaccines (TBV) aim to induce antibodies that can interrupt Plasmodium falciparum development in the mosquito midgut and thereby prevent onward malaria transmission. A limited number of TBV candidates have been identified and only three (Pfs25, Pfs230 and Pfs48/45) have entered clinical testing. While one of these candidates may emerge as a highly potent TBV candidate, it is premature to determine if they will generate sufficiently potent and sustained responses. It is therefore important to explore novel candidate antigens. We recently analyzed sera from naturally exposed individuals and found that the presence and/or intensity of antibodies against 12 novel putative surface expressed gametocyte antigens was associated with transmission reducing activity. In this study, protein fragments of these novel TBV candidates were designed and heterologously expressed in Drosophila melanogaster S2 cells and Lactococcus lactis. Eleven protein fragments, covering seven TBV candidates, were successfully produced. All tested antigens were recognized by antibodies from individuals living in malaria-endemic areas, indicating that native epitopes are present. All antigens induced antigen-specific antibody responses in mice. Two antigens induced antibodies that recognized a native protein in gametocyte extract, and antibodies elicited by four antigens recognized whole gametocytes. In particular, we found that antigen Pf3D7_0305300, a putative transporter, is abundantly expressed on the surface of gametocytes. However, none of the seven novel TBV candidates expressed here induced an antibody response that reduced parasite development in the mosquito midgut as assessed in the standard membrane feeding assay. Altogether, the antigen fragments used in this study did not prove to be promising transmission blocking vaccine constructs, but led to the identification of two gametocyte surface proteins that may provide new leads for studying gametocyte biology. |
format | Online Article Text |
id | pubmed-9259988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92599882022-07-08 Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates de Jong, Roos M. Singh, Susheel K. Teelen, Karina van de Vegte-Bolmer, Marga van Gemert, Geert-Jan Stone, Will J. R. Locke, Emily Plieskatt, Jordan Theisen, Michael Bousema, Teun Jore, Matthijs M. Front Immunol Immunology Malaria transmission blocking vaccines (TBV) aim to induce antibodies that can interrupt Plasmodium falciparum development in the mosquito midgut and thereby prevent onward malaria transmission. A limited number of TBV candidates have been identified and only three (Pfs25, Pfs230 and Pfs48/45) have entered clinical testing. While one of these candidates may emerge as a highly potent TBV candidate, it is premature to determine if they will generate sufficiently potent and sustained responses. It is therefore important to explore novel candidate antigens. We recently analyzed sera from naturally exposed individuals and found that the presence and/or intensity of antibodies against 12 novel putative surface expressed gametocyte antigens was associated with transmission reducing activity. In this study, protein fragments of these novel TBV candidates were designed and heterologously expressed in Drosophila melanogaster S2 cells and Lactococcus lactis. Eleven protein fragments, covering seven TBV candidates, were successfully produced. All tested antigens were recognized by antibodies from individuals living in malaria-endemic areas, indicating that native epitopes are present. All antigens induced antigen-specific antibody responses in mice. Two antigens induced antibodies that recognized a native protein in gametocyte extract, and antibodies elicited by four antigens recognized whole gametocytes. In particular, we found that antigen Pf3D7_0305300, a putative transporter, is abundantly expressed on the surface of gametocytes. However, none of the seven novel TBV candidates expressed here induced an antibody response that reduced parasite development in the mosquito midgut as assessed in the standard membrane feeding assay. Altogether, the antigen fragments used in this study did not prove to be promising transmission blocking vaccine constructs, but led to the identification of two gametocyte surface proteins that may provide new leads for studying gametocyte biology. Frontiers Media S.A. 2022-06-23 /pmc/articles/PMC9259988/ /pubmed/35812379 http://dx.doi.org/10.3389/fimmu.2022.909060 Text en Copyright © 2022 de Jong, Singh, Teelen, van de Vegte-Bolmer, van Gemert, Stone, Locke, Plieskatt, Theisen, Bousema and Jore https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology de Jong, Roos M. Singh, Susheel K. Teelen, Karina van de Vegte-Bolmer, Marga van Gemert, Geert-Jan Stone, Will J. R. Locke, Emily Plieskatt, Jordan Theisen, Michael Bousema, Teun Jore, Matthijs M. Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates |
title | Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates |
title_full | Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates |
title_fullStr | Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates |
title_full_unstemmed | Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates |
title_short | Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates |
title_sort | heterologous expression and evaluation of novel plasmodium falciparum transmission blocking vaccine candidates |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259988/ https://www.ncbi.nlm.nih.gov/pubmed/35812379 http://dx.doi.org/10.3389/fimmu.2022.909060 |
work_keys_str_mv | AT dejongroosm heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates AT singhsusheelk heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates AT teelenkarina heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates AT vandevegtebolmermarga heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates AT vangemertgeertjan heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates AT stonewilljr heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates AT lockeemily heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates AT plieskattjordan heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates AT theisenmichael heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates AT bousemateun heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates AT jorematthijsm heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates |